PHAR

Pharming Group N.V.

• Reuters·1d ago

  Pharming management to present at Needham Virtual Healthcare Conference

• Reuters·5d ago

  Pharming files 2025 annual report and Form 20-F

• Seeking Alpha·03/27 16:10

  Pharming granted EU backing for rare immunodeficiency therapy

• TipRanks·03/27 14:12

  Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS

• Reuters·03/27 11:42

  EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR HYMPAVZI

• Reuters·03/27 11:36

  Pharming Group gains positive EMA CHMP opinion for Joenja in APDS; European Commission decision expected in Q2 FY2026

• Benzinga·03/27 06:11

  Pharming's Joenja Edges Closer To Becoming First EU-Approved APDS Treatment After Positive CHMP Opinion With European Commission Decision Due Q2 2026

• Reuters·03/27 06:00

  PHARMING GROUP NV - FINAL EUROPEAN COMMISSION DECISION EXPECTED IN Q2 2026

• Dow Jones·03/24 15:31

  Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.

• TipRanks·03/24 15:30

  Analysts Offer Insights on Healthcare Companies: Pharming Group (PHAR) and Kura Oncology (KURA)

• Benzinga·03/24 15:20

  HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

• TipRanks·03/24 15:06

  Pharming announces approval of Joenja in Japan for patients aged 4 years and old

• TipRanks·03/24 12:06

  Pharming Group Wins Landmark Japan Approval for Joenja in Pediatric and Adult APDS

• NASDAQ·03/24 06:42

  Pharming Group's Leniolisib Gets Japan Approval To Treat APDS Patients Aged 4 Years And Older

• Benzinga·03/24 06:17

  Pharming Group's Joenja Approved In Japan As First Targeted Treatment For Activated PI3K Delta Syndrome In Patients Aged 4 Years And Older